Realcan Pharmaceutical Group Co., Ltd. (002589.SZ)

Growth (Per Share)

Revenue 5Y—
Revenue 3Y—
Earnings 5Y—
Earnings 3Y—
Dividend 5Y—
Dividend 3Y—

Capital Efficiency

ROIC—
ROE—
ROA—
ROTA—

Capital Structure

Market Cap5.43B
EV5.43B
Cash—
Current Ratio—
Debt/Equity—
Net Debt/EBITDA—
Show More

Select a metric from the list below to chart it

Income Statement
Dec '14
Dec '15
Dec '16
Dec '17
Dec '18
Dec '19
Dec '20
Dec '21
Dec '22
TTM
Revenue
1,134.0
1,420.1
2,274.9
3,392.8
4,940.4
5,135.5
3,962.3
3,067.4
1,793.2
1,498.9
Revenue % Chg.
31.4%
25.2%
60.2%
49.1%
45.6%
4.0%
-22.8%
-22.6%
-41.5%
-46.9%
Cost of Revenue
1,031.3
1,264.3
1,918.5
2,767.1
3,994.5
4,142.3
3,237.5
2,508.3
1,549.6
1,312.8
Gross Profit
102.7
155.8
356.5
625.7
945.9
993.2
724.9
559.2
243.5
186.1
Gross Profit Margin
9.1%
11.0%
15.7%
18.4%
19.1%
19.3%
18.3%
18.2%
13.6%
12.4%
R&D Expenses
—
—
—
—
—
1.0
1.3
1.7
3.3
3.1
Selling, General, & Admin Expenses
40.1
75.1
166.2
287.7
418.0
482.5
394.6
316.2
167.8
131.3
Other Expenses
15.1
19.4
39.8
60.5
113.7
131.8
96.5
90.5
62.7
62.3
Operating Income
47.6
61.3
150.5
263.7
393.5
369.6
248.2
189.4
9.8
-228.6
Operating Income Margin
4.2%
4.3%
6.6%
7.8%
8.0%
7.2%
6.3%
6.2%
0.5%
-15.2%
Total Other Income/Expenses Net
-12.3
-14.9
-22.6
0.0
-107.6
-354.7
-114.9
-121.7
-263.8
-41.9
Income Before Tax
35.2
46.4
127.9
263.7
285.9
14.9
133.3
67.7
-254.0
-270.5
Income Before Tax Margin
3.1%
3.3%
5.6%
7.8%
5.8%
0.3%
3.4%
2.2%
-14.2%
-18.0%
Income Tax Expense
8.7
11.0
29.6
64.4
99.7
78.3
42.4
12.1
-0.6
-7.1
Net Income
26.4
34.4
86.0
199.3
186.1
-63.4
91.0
55.6
-253.4
-263.4
Net Income Margin
2.3%
2.4%
3.8%
5.9%
3.8%
-1.2%
2.3%
1.8%
-14.1%
-17.6%
Weighted Avg. Shares Out
1,003.1
1,233.3
1,352.0
1,504.8
1,483.0
1,496.5
1,451.7
1,457.5
1,474.3
1,458.7
EPS
0.0
0.0
0.1
0.1
0.1
-0.0
0.1
0.0
-0.2
-0.2
EPS % Chg.
11.4%
6.0%
128.4%
108.3%
-5.5%
—
—
-39.5%
—
—
Weighted Avg. Shares Out Dil
1,003.1
1,233.3
1,352.0
1,504.8
1,483.0
1,496.5
1,451.7
1,457.5
1,474.3
1,458.7
EPS Diluted
0.0
0.0
0.1
0.1
0.1
-0.0
0.1
0.0
-0.2
-0.2
Interest Income
0.5
2.1
3.0
4.1
7.7
12.6
15.0
19.9
12.2
19.2
Interest Expense
11.3
12.9
15.3
28.6
83.9
107.4
86.0
80.8
59.4
54.7
EBIT
24.4
35.7
115.6
239.2
209.6
-79.8
62.4
6.8
-301.2
-305.9
EBIT Margin
2.2%
2.5%
5.1%
7.1%
4.2%
-1.6%
1.6%
0.2%
-16.8%
-20.4%
Depreciation & Amortization
3.6
6.3
11.5
30.4
34.1
40.0
42.1
46.5
-88.8
89.7
EBITDA
28.0
41.9
127.1
269.6
243.7
-39.8
104.5
53.3
-390.0
-216.2
EBITDA Margin
2.5%
3.0%
5.6%
7.9%
4.9%
-0.8%
2.6%
1.7%
-21.7%
-14.4%